Last reviewed · How we verify
NCT07463989
National Epidemiology of Cutaneous Lymphomas
trial in Lymphoma With Cutaneous Involvement in 1,000 participants. Currently enrolling.
13 May 2028
Quick facts
| Lead sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 13 May 2025 |
| Primary completion | 13 May 2028 |
| Estimated completion | 13 May 2030 |
| Sites | 1 location across Italy |
Conditions studied
- Lymphoma With Cutaneous Involvement — all drugs for Lymphoma With Cutaneous Involvement →
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →
Who can join
2 and older, any sex, with Lymphoma With Cutaneous Involvement. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rationale and Objective Primary cutaneous lymphomas are a rare and diverse group of cancers that start in the skin. While international data suggests an increase in cases since the 1970s, there is currently a lack of nationwide data in Italy regarding how common these diseases are and how they correlate with environmental or social factors.The main goal of this study is to create a national map of cutaneous lymphoma incidence and prevalence in Italy. Researchers want to identify if there are specific geographic areas with higher or lower numbers of cases and investigate potential links between the disease and environmental pollutants or other health conditions (comorbidities).Study Design This is a multicenter observational study that looks at both past and future data (retrospective and prospective). The study will involve approximately 1,000 patients across several Italian dermatology departments, with the IRCCS Azienda Ospedaliero-Universitaria di Bologna serving as the coordinating center.What the Study InvolvesData Collection: Researchers will review medical records from January 1, 2018, to December 31, 2022 (retrospective phase) and continue to collect data for patients enrolled over the next three years.Patient Participation: Patients will follow their standard clinical care paths. Information collected includes medical history, current and previous therapies, and laboratory results.Follow-up: Participants will be monitored for approximately two years to evaluate clinical outcomes and treatment responses.Expected Outcomes By analyzing this data, the study aims to improve clinical practice by providing a clearer understanding of how cutaneous lymphoma affects the Italian population based on age, sex, ethnicity, and location.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07463989
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials
Trials by the same sponsor.
- NCT06718049 — Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juveni · not yet recruiting
- NCT07490392 — Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantati · not yet recruiting
- NCT07483853 — Reliability and Validation of the WB-MRI Radiological Score in CRMO · recruiting
- NCT07479121 — These Studies Assess Surgeons' Physical and Ergonomic Workloads. Study 1 Compares Laparoscopic vs. Hugo RAS Robotic Appr · NA · not yet recruiting
- NCT07471009 — Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Sq · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07463989 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Last refreshed: 11 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07463989.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing